proctosigmoiditis

proctosigmoiditis

 [prok″to-sig″moi-di´tis]
inflammation of the rectum and sigmoid colon.

proc·to·sig·moi·di·tis

(prok'tō-sig'moy-dī'tis),
Inflammation of the sigmoid colon and rectum.
[procto- + sigmoid + G. -itis, inflammation]

proctosigmoiditis

/proc·to·sig·moi·di·tis/ (prok″to-sig″moi-di´tis) inflammation of the rectum and sigmoid colon.

proc·to·sig·moi·di·tis

(prok'tō-sig'moyd-ī'tis)
Inflammation of the sigmoid colon and rectum.
[procto- + sigmoid + G. -itis, inflammation]

proctosigmoiditis

inflammation of the rectum and sigmoid colon.
References in periodicals archive ?
18) and no difference in T-score was observed between proctosigmoiditis and extensive colitis.
Biopharmaceutical company Cellceutix Corporation (OtherOTC:CTIX) disclosed on Tuesday the completion of enrolment under the second cohort of the Phase 2 open label Proof-of-Concept trial evaluating Brilacidin for treating mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis, two types of inflammatory bowel disease.
Patients with proctitis and proctosigmoiditis have little or no increased risk of cancer compared with the general population; therefore, the usual screening program for colorectal cancer for the general population may suffice for these patients.
Martin P, Manley PN, Depew WT, et al: Isotretinoin-associated proctosigmoiditis.
Currently we are targeting submission of the NDA for budesonide foam for the treatment of moderate ulcerative proctitis or proctosigmoiditis during the third quarter of 2013.
The company said Rowasa (mesalamine) rectal suspension enema 4g/60ml is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.
9) Left-sided UC confers an intermediate degree of risk for neoplasia, whereas proctitis and proctosigmoiditis confer little or none.
Distal ulcerative colitis is characterised as either ulcerative proctitis (inflammation localised to the rectum) or ulcerative proctosigmoiditis (inflammation localised to the distal colon and rectum).
Patient enrollment continues in our two identically designed Phase 3, multi-center, double-blind, randomized, placebo-controlled studies evaluating the effectiveness and safety of budesonide rectal foam for the treatment of mild to moderate ulcerative proctitis or proctosigmoiditis.
In addition, patient enrollment is ongoing in our two identically designed Phase 3, multi-center, double-blind, randomized, placebo-controlled studies evaluating the effectiveness and safety of budesonide rectal foam for the treatment of mild to moderate ulcerative proctitis or proctosigmoiditis.
In early October we submitted an IND to the FDA to conduct two identically designed Phase 3, multi-center, double-blind, randomized, placebo-controlled studies evaluating the effectiveness and safety of budesonide rectal foam for the treatment of mild to moderate ulcerative proctitis or proctosigmoiditis.